Abstract
In this review, the role of nuclear factor-κB (NF-κB) in hepatocarcinogenesis is examined. The administration of several hepatic tumor promoters leads to the activation of NF-κB in the liver of rats and mice. Many studies support the hypothesis that the activation of NF-κB in the liver is inhibited by antioxidants. The role of NF-κB in hepatocarcinogenesis has been examined using NF-κB overexpression and knockout models. The role of NF-κB in liver carcinogenesis is complex; some models show that NF-κB contributes to carcinogenesis whereas others see no effect or an inhibition. Overall, although hepatic tumor promoting agents can activate NF-κB and this activation can be inhibited by antioxidants, the significance of this activation is unclear.
Keywords: Antioxidants, carcinogenesis, hepatocellular carcinomas, IκB kinase, NF-κB, vitamin E, peroxisome proliferator-activated receptor, TANK-binding kinase 1, tumor necrosis factor-α, constitutive androstane receptor, carbon tetrachloride, ciprofibrate, dimethylaminoazobenzene, diethylnitrosamine, glutathione peroxidase, reduced glutathione
Current Cancer Drug Targets
Title:Role of NF-κB in Hepatocarcinogenesis and Its Potential Inhibition by Dietary Antioxidants
Volume: 12 Issue: 9
Author(s): Howard Perry Glauert
Affiliation:
Keywords: Antioxidants, carcinogenesis, hepatocellular carcinomas, IκB kinase, NF-κB, vitamin E, peroxisome proliferator-activated receptor, TANK-binding kinase 1, tumor necrosis factor-α, constitutive androstane receptor, carbon tetrachloride, ciprofibrate, dimethylaminoazobenzene, diethylnitrosamine, glutathione peroxidase, reduced glutathione
Abstract: In this review, the role of nuclear factor-κB (NF-κB) in hepatocarcinogenesis is examined. The administration of several hepatic tumor promoters leads to the activation of NF-κB in the liver of rats and mice. Many studies support the hypothesis that the activation of NF-κB in the liver is inhibited by antioxidants. The role of NF-κB in hepatocarcinogenesis has been examined using NF-κB overexpression and knockout models. The role of NF-κB in liver carcinogenesis is complex; some models show that NF-κB contributes to carcinogenesis whereas others see no effect or an inhibition. Overall, although hepatic tumor promoting agents can activate NF-κB and this activation can be inhibited by antioxidants, the significance of this activation is unclear.
Export Options
About this article
Cite this article as:
Perry Glauert Howard, Role of NF-κB in Hepatocarcinogenesis and Its Potential Inhibition by Dietary Antioxidants, Current Cancer Drug Targets 2012; 12 (9) . https://dx.doi.org/10.2174/15680096112091160
DOI https://dx.doi.org/10.2174/15680096112091160 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Long-circulating Targeted Nanoparticles for Cancer Therapy
Current Nanoscience Tyrosine Kinase Mutations in Human Cancer
Current Molecular Medicine A Uniquely Modified DKL-based Peptide Probe for Positron Emission Tomography Imaging
Current Pharmaceutical Design Brutons Tyrosine Kinase as a New Therapeutic Target
Anti-Cancer Agents in Medicinal Chemistry Acid Ceramidase as a Chemotherapeutic Target to Overcome Resistance to the Antitumoral Effect of Choline Kinase α Inhibition
Current Cancer Drug Targets Biomedical Applications of Nanomaterials as Therapeutics
Current Medicinal Chemistry Segmentation and Texture Analysis for Efficient Classification of Breast Tumors from Sonograms
Current Signal Transduction Therapy The VHL Tumor Suppressor: Master Regulator of HIF
Current Pharmaceutical Design Editorial: Lipoprotein (a), More than Just Cholesterol?
Current Medicinal Chemistry Editorial (Thematic Issue: Novel Anticancer Drugs from Nature)
Current Medicinal Chemistry Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer
Current Cancer Drug Targets Repeated Transarterial Chemoembolization with Degradable Starch Microspheres (DSMs-TACE) of Unresectable Hepatocellular Carcinoma: A Prospective Pilot Study
Current Medical Imaging Treatment Strategies for Fatty Liver Diseases
Reviews on Recent Clinical Trials Suppression of the Viability and Proliferation of HepG2 Hepatocellular Carcinoma Cell Line by Konjac Glucomannan
Anti-Cancer Agents in Medicinal Chemistry Application in Electrochemistry of Graphene-Modified Electrodes
Micro and Nanosystems Liposomal Formulation for Dermal and Transdermal Drug Delivery: Past, Present and Future
Recent Patents on Drug Delivery & Formulation Preface [Hot topic: Mitochondria as a Target of Medicinal Chemistry (Guest Editor: Dongchon Kang)]
Current Medicinal Chemistry Challenges and Opportunities for Cancer Vaccines in the Current NSCLC Clinical Scenario
Current Topics in Medicinal Chemistry MicroRNA miR-122 as a Therapeutic Target for Oligonucleotides and Small Molecules
Current Medicinal Chemistry Carbonyl-Scavenging Drugs & Protection Against Carbonyl Stress-Associated Cell Injury
Mini-Reviews in Medicinal Chemistry